Multimerin-2 maintains vascular stability and permeability

Matrix Biol. 2020 May:87:11-25. doi: 10.1016/j.matbio.2019.08.002. Epub 2019 Aug 15.

Abstract

Multimerin-2 is an extracellular matrix glycoprotein and member of the elastin microfibril interface-located (EMILIN) family of proteins. Multimerin-2 is deposited along blood vessels and we previously demonstrated that it regulates the VEGFA/VEGFR2 signaling axis and angiogenesis. However, its role in modulating vascular homeostasis remains largely unexplored. Here we identified Multimerin-2 as a key molecule required to maintain vascular stability. RNAi knockdown of Multimerin-2 in endothelial cells led to cell-cell junctional instability and increased permeability. Mechanistically cell-cell junction dismantlement occurred through the phosphorylation of VEGFR2 at Tyr951, activation of Src and phosphorylation of VE-cadherin. To provide an in vivo validation for these in vitro effects, we generated Multimerin-2-/- (Mmrn2-/-) mice. Although Mmrn2-/- mice developed normally and displayed no gross abnormalities, endothelial cells displayed cell junctional defects associated with increased levels of VEGFR2 phospho-Tyr949 (the murine counterpart of human Tyr951), impaired pericyte recruitment and increased vascular leakage. Of note, tumor associated vessels were defective in Mmrn2-/- mice, with increased number of small and often collapsed vessels, concurrent with a significant depletion of pericytic coverage. Consequently, the Mmrn2-/- vessels were less perfused and leakier, leading to increased tumor hypoxia. Chemotherapy efficacy was markedly impaired in Mmrn2-/- mice and this was associated with poor drug delivery to the tumor xenografts. Collectively, our findings demonstrate that Multimerin-2 is required for proper vessel homeostasis and stabilization, and unveil the possibility to utilize expression levels of this glycoprotein in predicting chemotherapy efficacy.

Keywords: angiogenesis; extracellular matrix; tumor growth; tumor microenvironment; vascular homeostasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, CD / metabolism*
  • Antigens, Surface / genetics*
  • Antigens, Surface / metabolism
  • Cadherins / metabolism*
  • Cell Line, Tumor
  • Cisplatin / administration & dosage
  • Cisplatin / pharmacology
  • Drug Therapy
  • Extracellular Matrix Proteins / genetics*
  • Extracellular Matrix Proteins / metabolism
  • Gene Knockout Techniques
  • Human Umbilical Vein Endothelial Cells
  • Humans
  • Intercellular Junctions
  • Intercellular Signaling Peptides and Proteins / genetics*
  • Intercellular Signaling Peptides and Proteins / metabolism
  • Melanoma / blood supply*
  • Melanoma / drug therapy
  • Melanoma / genetics
  • Melanoma / metabolism
  • Membrane Glycoproteins / genetics*
  • Membrane Glycoproteins / metabolism
  • Mice
  • Neoplasm Transplantation
  • Phosphorylation
  • Tumor Hypoxia / drug effects
  • Vascular Endothelial Growth Factor Receptor-2 / metabolism*

Substances

  • Antigens, CD
  • Antigens, Surface
  • Cadherins
  • EMILIN3 protein, human
  • Extracellular Matrix Proteins
  • Intercellular Signaling Peptides and Proteins
  • Membrane Glycoproteins
  • Mmrn2 protein, mouse
  • cadherin 5
  • Vascular Endothelial Growth Factor Receptor-2
  • Cisplatin